Ngenla (Somatrogon: Pfizer) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, And Forecasts, 2020-2025, 2025-2030F, 2035F

(MENAFN- GlobeNewsWire - Nasdaq) Key opportunities in the market include the rising demand for long-acting growth hormone therapies, expanding biologics manufacturing, and improved patient adherence. Asia-Pacific presents the fastest growth potential, with personalized endocrine care and localized production offering strategic advantages.

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Ngenla Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets's offering.

The Ngenla market, driven by the increasing diagnosis of growth hormone deficiency (GHD), is poised for substantial growth. Historic growth stems from improved diagnostic rates, the established daily use of somatropin therapies, advancements in recombinant DNA technology, and heightened awareness in pediatric endocrinology. The forecast period anticipates rising demand for long-acting endocrine therapies and increased adult GHD diagnosis rates, alongside a focus on quality-of-life outcomes and expanded biologics manufacturing capacity.

Ngenla, a long-acting recombinant human growth hormone (somatrogon), responds to these needs by providing sustained hormone release through once-weekly injections. This significantly reduces the burden of daily treatment, enhances adherence, and promotes growth in children with GHD. According to the National Library of Medicine, pediatric GHD affects 1 in 3,500 to 1 in 10,000 children, which underscores the growing market potential for Ngenla as its prevalence increases.

The market is characterized by its focus on long-acting therapies, aimed at improving adherence and outcomes for both pediatric and adult GHD patients. Notably, in June 2023, Pfizer Inc. and OPKO Health Inc. secured FDA approval for Ngenla, a weekly growth hormone analog for pediatric patients aged three and up with growth failure due to insufficient endogenous hormone secretion.

Significant industry developments include the partnership between OPKO Health and HealthCare Royalty through non-dilutive note purchase agreements, allowing OPKO to maintain significant profit share from Ngenla while optimizing long-term benefits. Pfizer Inc. remains a major player in the Ngenla market.

Geographical insights reveal North America as the largest region in the Ngenla market by 2025, with Asia-Pacific projected as the fastest-growing region. Key areas within the report focus on Asia-Pacific, Western and Eastern Europe, North America, South America, the Middle East, and Africa, covering countries like Australia, India, China, South Korea, Japan, UK, France, Germany, USA, and Canada.

Tariffs affect the Ngenla market by escalating costs associated with importing biologic raw materials and production components. While these tariffs pose pricing pressures, they also encourage localized biologics manufacturing and strengthened domestic supply chains, offering long-term benefits for hormone therapy production.

The market analysis extends to sales of prefilled injection pens and somatrogon solutions, considering 'factory gate' values. Revenues represent consumption values within specific geographies, embracing sales, grants, or donations under the umbrella of the specified market.

Ngenla addresses several conditions, including GHD, Turner syndrome, Prader-Willi syndrome, and small for gestational age (SGA). It's distributed through hospital, retail, and online pharmacies, catering to diverse patient groups, from pediatric to adult populations.

The industry analysis provides insights into market size, regional shares, and competitor landscapes, delivering a comprehensive view of the Ngenla market and its future trajectory.

Key Benefits of the Report:

• Obtain a global perspective with coverage of 16 geographies.
• Evaluate the impact of macro factors like geopolitical tensions, trade policies, inflation, and interest rate changes.
• Formulate regional strategies with data-driven analysis.
• Identify potential growth segments for investment.
• Leverage forecast data to outsmart competitors.
• Understand customer demographics via end-user analytics.
• Benchmark against key competitors on market share, innovation, and brand strength.
• Analyze market potential through TAM and attractiveness scores.
• Utilize data for high-quality presentations and strategic decisions.
• Receive updated reports with the latest data in Excel format for seamless data extraction.

Report Scope:

• By Indication: Growth Hormone Deficiency, Turner Syndrome, Prader-Willi, Small For Gestational Age
• By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• By End User: Pediatric Patients, Adult Patients

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN13032026004107003653ID1110856756